文献速递瓣膜外科

三种主动脉生物瓣膜再干预率的比较

Reintervention After Aortic Valve Replacement: Comparison of 3 Aortic Bioprostheses.
PubMed 文献 · Ann Thorac Surg · 2019-12-14

共植入2004枚瓣膜,CE组无事件生存率显著高于Trifecta和Mitroflow组(P < .0001)。CE组再干预仅因感染性心内膜炎,而Trifecta和Mitroflow组主要因结构性瓣膜衰败。

要点

  • CE组无事件生存率显著高于Trifecta和Mitroflow组。
  • CE组再干预原因均为感染性心内膜炎,Trifecta和Mitroflow组主要为结构性瓣膜衰败。
  • 年龄和瓣膜类型与无事件生存率降低相关。

核心结论

  • CE生物瓣膜植入后的免再干预率显著高于Trifecta和Mitroflow生物瓣膜。

主要发现

  • 共植入2004枚生物主动脉瓣膜,包括923枚CE、719枚Trifecta和362枚Mitroflow。
  • CE组无事件生存率为917例(99.3%),显著高于Trifecta组的685例(95.3%)和Mitroflow组的340例(93.9%)(P < .0001)。
  • CE组再干预原因仅为感染性心内膜炎(6例,100%),而Trifecta组(14例,41.2%)和Mitroflow组(14例,63.6%)最常见的再干预原因为结构性瓣膜衰败。
  • Cox回归分析显示,年龄(HR 0.9;95%CI 0.9-0.9;P < .0001)和瓣膜类型(Trifecta:HR 6.3;95%CI 2.6-15.2;P < .0001;Mitroflow:HR 6.0;95%CI 2.4-15.1;P < .0001)与较低的无事件生存率相关。

临床怎么用

  • 在选择主动脉生物瓣膜时,CE瓣膜可能具有更低的再干预风险。
  • 对于Trifecta和Mitroflow瓣膜,应关注结构性瓣膜衰败导致的再干预。

局限性

  • 需要更大规模患者群体和长期随访来确认瓣膜的耐久性和长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The decision to implant a biological valve prosthesis is influenced by the issue of durability. We investigated the rate and the cause of reintervention in 3 different aortic valve bioprostheses. METHODS: The study included all patients who underwent aortic valve replacement with a biological valve prosthesis between October 2009 and December 2018. Three different bioprostheses were compared: Carpentier-Edwards (CE) Magna Ease (Edwards Lifesciences, Irvine, CA), Trifecta (St. Jude Medical, St Paul, MN), and Mitroflow (LivaNova, London, United Kingdom). The primary end point was the rate of explantation. The degree of event-free survival and possible predictors for reintervention were also analyzed using Cox regression analysis. RESULTS: In total, 2004 biological aortic valves were implanted, including 923 CE, 719 Trifecta, and 362 Mitroflow bioprostheses. The CE group had a significantly higher degree of event-free survival (917 [99.3%]) compared with the Trifecta (685 [95.3%]) and Mitroflow (340 [93.9%]) groups (P < .0001). The only cause of reintervention in the CE group was prosthetic valve endocarditis (6 [100%]), whereas structural valve deterioration was the most common cause of reintervention in the Trifecta (14 [41.2%]) and Mitroflow (14 [63.6%]) groups. Cox regression analysis revealed that age (hazard ratio [HR] 0.9; 95% confidence interval [CI], 0.9-0.9; P < .0001) and type of prosthesis (Trifecta: HR, 6.3; 95% CI, 2.6-15.2; P < .0001; Mitroflow: HR, 6.0, 95% CI, 2.4-15.1; P < .0001) were associated with lower event-free survival. CONCLUSIONS: The freedom from reintervention after implantation of the CE bioprosthesis is significantly greater than that of the Trifecta and Mitroflow bioprostheses. Further investigations with larger patient populations and long-term follow-up are required to establish their durability and long-term efficacy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Lam KY, Koene B, Timmermans N, et al. Reintervention After Aortic Valve Replacement: Comparison of 3 Aortic Bioprostheses. Ann Thorac Surg. 2019. PMID: 31846642. doi:10.1016/j.athoracsur.2019.10.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。